Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $47.4 million.

  • Lineage Cell Therapeutics' Non-Current Assets fell 2381.94% to $47.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.3 million, marking a year-over-year decrease of 1265.29%. This contributed to the annual value of $62.2 million for FY2024, which is 57.05% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Non-Current Assets stood at $47.4 million for Q3 2025, which was down 2381.94% from $47.0 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-Current Assets peaked at $63.6 million during Q1 2023, and registered a low of $4.9 million during Q4 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $62.6 million (2023), whereas its average is $55.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 100308.48% in 2023, then plummeted by 2476.61% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-Current Assets (Quarter) stood at $4.9 million in 2021, then rose by 16.44% to $5.7 million in 2022, then soared by 1003.08% to $62.6 million in 2023, then dropped by 0.57% to $62.2 million in 2024, then dropped by 23.85% to $47.4 million in 2025.
  • Its last three reported values are $47.4 million in Q3 2025, $47.0 million for Q2 2025, and $61.8 million during Q1 2025.